FR2270892A1 - Vaccines from attenuated viruses - which have been serially incubated with yeast cells, especially Saccharomyces cerevisiae - Google Patents

Vaccines from attenuated viruses - which have been serially incubated with yeast cells, especially Saccharomyces cerevisiae

Info

Publication number
FR2270892A1
FR2270892A1 FR7416598A FR7416598A FR2270892A1 FR 2270892 A1 FR2270892 A1 FR 2270892A1 FR 7416598 A FR7416598 A FR 7416598A FR 7416598 A FR7416598 A FR 7416598A FR 2270892 A1 FR2270892 A1 FR 2270892A1
Authority
FR
France
Prior art keywords
saccharomyces cerevisiae
virus
yeast cells
vaccines
attenuated viruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7416598A
Other languages
French (fr)
Other versions
FR2270892B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INST FRANCAIS D IMMUNOLOGIE
Original Assignee
INST FRANCAIS D IMMUNOLOGIE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INST FRANCAIS D IMMUNOLOGIE filed Critical INST FRANCAIS D IMMUNOLOGIE
Priority to FR7416598A priority Critical patent/FR2270892A1/en
Publication of FR2270892A1 publication Critical patent/FR2270892A1/en
Application granted granted Critical
Publication of FR2270892B1 publication Critical patent/FR2270892B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Modified viruses are prepd. from vertebrates by incubating a suspension of the virus with yeast cells in a culture medium, (esp. Saccharomyces cerevisiae). Process ensures destruction of viral or tumoral genetic matl. which may render dangerous any vaccine prepd. from the virus. The process may be applied to adenovirus; herpes, vaccinia, Rous sarcoma, poliomyelitis, rabies, measles, influenza, Newcastle disease and hepatitis viruses. Prefd. incubation conditions are 35 degrees C for 72-120h. at pH 6-8. Attenuation of the virus is achieved by formation of a new nucleoprotein from viral nucleic acid and protein from the host cells.
FR7416598A 1974-05-14 1974-05-14 Vaccines from attenuated viruses - which have been serially incubated with yeast cells, especially Saccharomyces cerevisiae Granted FR2270892A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7416598A FR2270892A1 (en) 1974-05-14 1974-05-14 Vaccines from attenuated viruses - which have been serially incubated with yeast cells, especially Saccharomyces cerevisiae

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7416598A FR2270892A1 (en) 1974-05-14 1974-05-14 Vaccines from attenuated viruses - which have been serially incubated with yeast cells, especially Saccharomyces cerevisiae

Publications (2)

Publication Number Publication Date
FR2270892A1 true FR2270892A1 (en) 1975-12-12
FR2270892B1 FR2270892B1 (en) 1978-02-03

Family

ID=9138792

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7416598A Granted FR2270892A1 (en) 1974-05-14 1974-05-14 Vaccines from attenuated viruses - which have been serially incubated with yeast cells, especially Saccharomyces cerevisiae

Country Status (1)

Country Link
FR (1) FR2270892A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0072318A2 (en) * 1981-08-04 1983-02-16 The Regents Of The University Of California Synthesis of human virus antigens by yeast
EP0073657A1 (en) * 1981-08-31 1983-03-09 Genentech, Inc. Preparation of hepatitis B surface antigen in yeast
US4803164A (en) * 1981-08-31 1989-02-07 Genentech, Inc. Preparation of hepatitis b surface antigen in yeast
US4820642A (en) * 1983-04-04 1989-04-11 The Regents Of The University Of California Amplified expression vector

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0072318A2 (en) * 1981-08-04 1983-02-16 The Regents Of The University Of California Synthesis of human virus antigens by yeast
EP0072318A3 (en) * 1981-08-04 1983-03-16 The Regents Of The University Of California Synthesis of human virus antigens by yeast
EP0073657A1 (en) * 1981-08-31 1983-03-09 Genentech, Inc. Preparation of hepatitis B surface antigen in yeast
US4803164A (en) * 1981-08-31 1989-02-07 Genentech, Inc. Preparation of hepatitis b surface antigen in yeast
US4820642A (en) * 1983-04-04 1989-04-11 The Regents Of The University Of California Amplified expression vector

Also Published As

Publication number Publication date
FR2270892B1 (en) 1978-02-03

Similar Documents

Publication Publication Date Title
Tytell et al. Inducers of interferon and host resistance. 3. Double-stranded RNA from reovirus type 3 virions (reo 3-RNA).
Nishioka et al. Degradation of cellular mRNA during infection by herpes simplex virus.
US7524676B2 (en) Large scale productions of virus antigen
Nakajima et al. Origin of small RNA in von Magnus particles of influenza virus
Bean Jr et al. Transcriptase activity and genome composition of defective influenza virus
CA2234208A1 (en) Influenza vaccine
NO20022500D0 (en) Process for the preparation of viruses or viral proteins for use of vaccines
Vaidya et al. Murine mammary tumor virus: characterization of infection of nonmurine cells
Nagata et al. Temperature-sensitive phenomenon of viral maturation observed in BHK cells persistently infected with HVJ
US3674864A (en) Process for stabilizing preparations of interfering viruses
Baron et al. Host cell species specificity of mouse and chicken interferons
Don et al. Specific increase in polyamine levels in chick embryo cells transformed by Rous sarcoma virus
FR2270892A1 (en) Vaccines from attenuated viruses - which have been serially incubated with yeast cells, especially Saccharomyces cerevisiae
Nagai et al. The pathogenicity of Newcastle disease virus isolated from migrating and domestic ducks and the susceptibility of the viral glycoproteins to proteolytic cleavage
Bikel et al. Proteins of Newcastle disease virus and of the viral nucleocapsid
Robertson et al. Assessing the significance of reverse transcriptase activity in chick cell-derived vaccines
Oxford Polypeptide composition of influenza B viruses and enzymes associated with the purified virus particles
Scheele et al. Electrophoretic analysis of the RNA of avian tumor viruses
Gupta et al. Alternate capping mechanisms for transcription of spring viremia of carp virus: evidence for independent mRNA initiation
Munemitsu et al. Biosynthesis of reovirus-specified polypeptides multiplication rate but not yield of reovirus serotypes 1 and 3 correlates with the level of virus-mediated inhibition of cellular protein synthesis
Nair et al. Preliminary observations pertaining to polyadenylation of rhinovirus RNA
Abraham The effect of ultraviolet radiation on the primary transcription of influenza virus messenger RNAs
Nagata et al. In vitro synthesis of influenza viral RNA: biochemical complementation assay of factors required for influenza virus replication
Siegert et al. Direct evidence for messenger activity of influenza virion RNA
GB660109A (en) Improvements in or relating to the treatment of allantoic fluid containing a propagated virus together with non-viral proteins to obtain the virus in purified and viable from for use in a vaccine

Legal Events

Date Code Title Description
ST Notification of lapse